reversed-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-25. Numbers and descriptions here follow the published literature rather than marketing material.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Kaas advised President Hindenburg not to continue Papen's "administration of conflict"; he advocated "national concentration including the National Socialists", but did not comment on an alternative Chancellor, since he considered that the "personal prerogative of the President". Hindenburg's negotiations with Hitler failed, but so did Kaas's attempt to form a coalition in parliament. By avoiding a clear statement, Hitler managed to pin the blame for this failure on the DNVP's Alfred Hugenberg, who had rejected Kaas's proposals. Since the cabinet had refused to support Papen's planned coup d'état by a permanent dissolution of the Reichstag, in December Hindenburg appointed General Kurt von Schleicher as Chancellor. Schleicher tried to form a "Querfront" (an alliance involving willing members of both left-wing and right-wing parties), which failed. Schleicher then revived Papen's proposed coup d'état, which the Centre Party refused to condone, as did the other parties. Under these circumstances, Hindenburg refused to back the coup, and Schleicher accordingly resigned on 28 January 1933.
Quantum dots (QDs) or semiconductor nanocrystals are semiconductor particles a few nanometres in size with optical and electronic properties that differ from those of larger particles via quantum mechanical effects. They are a central topic in nanotechnology and materials science. When a quantum dot is illuminated by UV light, an electron in the quantum dot can be excited to a state of higher energy. In the case of a semiconducting quantum dot, this process corresponds to the transition of an electron from the valence band to the conduction band. The excited electron can drop back into the valence band releasing its energy as light. This light emission (photoluminescence) is illustrated in the figure on the right. The color of that light depends on the energy difference between the discrete energy levels of the quantum dot in the conduction band and the valence band. In other words, a quantum dot can be defined as a structure on a semiconductor which is capable of confining electrons in three dimensions, enabling the ability to define discrete energy levels. The quantum dots are tiny crystals that can behave as individual atoms, and their properties can be manipulated. Nanoscale materials with semiconductor properties tightly confine either electrons or electron holes. The confinement is similar to a three-dimensional particle in a box model. The quantum dot absorption and emission features correspond to transitions between discrete quantum mechanically allowed energy levels in the box that are reminiscent of atomic spectra.
== See also == Family tree of German monarchs – he was related to every other ruler of Germany List of coupled cousins Austro-Hungarian entry into World War I Franc Jozeph Island, island in Albania named in honor of the Emperor. Order of St. George (Habsburg-Lorraine) Franz Josef Glacier was named after Emperor Franz Joseph I by the German geologist Julius von Haast in 1865.
Sources: en.wikipedia.org
== Selected publications == Bolisetty, S.; Peydayesh, M.; Mezzenga, R. (2019). “Sustainable technologies for water purification from heavy metals: review and analysis.” Chemical Society Reviews 48 (2): 463–487. Wei, G.; Su, Z.; Reynolds, N. P.; Arosio, P.; Hamley, I. W.; Gazit, E.; Mezzenga, R. (2017). “Self-assembling peptide and protein amyloids: from structure to tailored function in nanotechnology.” Chemical Society Reviews 46 (15): 4661–4708. Mezzenga, R.; Schurtenberger, P.; Burbidge, A.; Michel, M. (2005). “Understanding foods as soft materials.” Nature Materials 4 (10): 729–740. Nasrabadi, M. N.; Doost, A. S.; Mezzenga, R. (2021). “Modification approaches of plant-based proteins to improve their techno-functionality and use in food products.” Food Hydrocolloids 118: 106789. Adamcik, J.; Jung, J. M.; Flakowski, J.; De Los Rios, P.; Dietler, G.; Mezzenga, R. (2010). “Understanding amyloid aggregation by statistical analysis of atomic force microscopy images.” Nature Nanotechnology 5 (6): 423–428. Bolisetty, S.; Mezzenga, R. (2016). “Amyloid–carbon hybrid membranes for universal water purification.” Nature Nanotechnology 11 (4): 365–371. Cao, Y.; Mezzenga, R. (2019). “Food protein amyloid fibrils: origin, structure, formation, characterization, applications and health implications.” Advances in Colloid and Interface Science 269: 334–356. I. Usov, G. Nyström, J. Adamcik, S. Handschin, C. Schütz, A. Fall, L. Bergström & R. Mezzenga (2015). Understanding nanocellulose chirality and structure–properties relationship at the single fibril level.
The word metagenics uses the prefix meta and the suffix gen. Literally, it means "the creation of something which creates". In the context of biotechnology, metagenics is the practice of engineering organisms to create a specific enzyme, protein, or other biochemical from simpler starting materials. The genetic engineering of E. coli with the specific task of producing human insulin from starting amino acids is an example. E. coli has also been engineered to digest plant biomass and use it to produce hydrocarbons in order to synthesize biofuels. The applications of metagenics on E. coli also include higher alcohols, fatty-acid based chemicals and terpenes.
== Stages of progress in nanotechnology == In 2005, Mihail Roco, one of the architects of the USA's National Nanotechnology Initiative, proposed four states of nanotechnology that seem to parallel the technical progress of the Industrial Revolution, of which productive nanosystems is the most advanced. 1. Passive nanostructures - nanoparticles and nanotubes that provide added strength, electrical and thermal conductivity, toughness, hydrophilic/phobic and/or other properties that emerge from their nanoscale structure. 2. Active nanodevices - nanostructures that change states in order to transform energy, information, and/or to perform useful functions. There is some debate about whether or not state-of-the art integrated circuits qualify here, since they operate despite emergent nanoscale properties, not because of them. Therefore, the argument goes, they don't qualify as "novel" nanoscale properties, even though the devices themselves are between one and a hundred nanometers. 3. Complex nanomachines - the assembly of different nanodevices into a nanosystem to accomplish a complex function. Some would argue that Zettl's machines fit in this category; others argue that modern microprocessors and FPGAs also fit. 4. Systems of nanosystems/Productive nanosystems - these will be complex nanosystems that produce atomically precise parts for other nanosystems, not necessarily using novel nanoscale-emergent properties, but well-understood fundamentals of manufacturing. Because of the discrete (i.e.
=== Transmasculine individuals === Numerous studies have recorded the proliferation of prostate tissue in transmasculine individuals undergoing testosterone therapy. A 2022 study concluded that "one hundred percent of vaginal specimens obtained from transmasculine individuals on testosterone therapy (21/21 cases) demonstrated prostatic metaplasia" and notes, congruously with similar studies, that further research in this area is warranted so as to contribute to higher standards of care for transgender patients, and so that the presence of this tissue does not register to healthcare providers as an abnormality.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.